A new experimental KRAS inhibitor, daraxonrasib, significantly extends survival in metastatic pancreatic cancer, with a median overall survival of 13.2 months versus 6.7 months on standard chemotherapy.

In the Phase 3 trial presented at the ASCO Annual Meeting in June 2026, patients on daraxonrasib showed a substantial survival advantage, marking a meaningful advance for a disease with historically poor outcomes.

UT Southwestern Medical Center in Dallas highlighted the potential historic breakthrough, as the trial results nearly doubled median survival for metastatic pancreatic cancer compared with conventional therapy.

Background context notes that pancreatic cancer often develops from gene mutations, with RAS proteins driving uncontrolled cell growth.

Reported sources include Revolution Medicines, UCHealth, Cedars-Sinai, the American Cancer Society, and USA TODAY research.

Daraxonrasib is a KRAS inhibitor that traps the KRAS mutation in an inactive form, addressing a mutation present in the vast majority of pancreatic cancers.

The drug is being explored for other RAS-mutant cancers, including lung, colorectal, ovarian, endometrial cancers, and cholangiocarcinoma.

Daraxonrasib is an oral daily pill, representing a paradigm shift in treating historically hard-to-target RAS-mutant cancers.

An FDA early access program for daraxonrasib was approved on April 30, 2026, with formal approval anticipated later in 2026 if results remain favorable.

Pancreatic cancer remains highly lethal, with tens of thousands of expected US deaths in 2026, underscoring the potential impact of this therapy.

The drug targets RAS mutations by binding the active RAS protein, effectively blocking growth signals.

The trial results were published in the New England Journal of Medicine on May 31, 2026, showing a 60% reduction in the risk of death for patients treated with daraxonrasib.